The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 28, 2021
Filed:
Oct. 17, 2018
Applicants:
Alnylam Pharmaceuticals, Inc., Cambridge, MA (US);
Eth Zurich, Zurich, CH;
Inventors:
Muthiah Manoharan, Weston, MA (US);
Markus Stoffel, Herrliberg, CH;
Mehrpouya Balaghy Mobin, Cologne, DE;
Assignees:
Alnylam Pharmaceuticals, Inc., Cambridge, MA (US);
ETH Zurich, Zurich, CH;
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/713 (2006.01); C12N 15/113 (2010.01); A61P 3/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/713 (2013.01); A61P 3/06 (2018.01); C12N 15/113 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/3125 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/351 (2013.01); C12N 2310/3521 (2013.01); C12N 2310/3533 (2013.01);
Abstract
The invention relates to double stranded ribonucleic acid (dsRNA) agents and compositions targeting a High Density Lipoprotein Binding Protein (Hdlbp/Vigilin) gene, as well as methods of inhibiting expression of Hdlbp/Vigilin and methods of treating subjects having a disorder of lipid metabolism, such as mixed hyperlipidemia, hypertriglyceridemia or hypercholesterolemia, using such dsRNA agents and compositions.